CBLI Share Price

Open 1.51 Change Price %
High 1.62 1 Day 0.00 0.00
Low 1.50 1 Week -0.04 -2.50
Close 1.56 1 Month -0.05 -3.11
Volume 22178 1 Year -2.65 -62.95
52 Week High 4.58
52 Week Low 0.00
CBLI Important Levels
Resistance 2 1.67
Resistance 1 1.63
Pivot 1.56
Support 1 1.49
Support 2 1.45
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
MSFT 59.66 4.21%
MSFT 59.66 4.21%
MSFT 59.66 4.21%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
HMNY 9.90 76.47%
LOCM 0.09 50.00%
SCHS 0.12 33.33%
KONE 6.59 29.22%
WRES 0.09 28.57%
ALKS 55.62 27.83%
QKLS 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
PGRX 0.04 -42.86%

Cleveland BioLabs, Inc. (NASDAQ: CBLI)

CBLI Technical Analysis 5
As on 21st Oct 2016 CBLI Share Price closed @ 1.56 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.72 & Strong Sell for SHORT-TERM with Stoploss of 1.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
CBLI Target for October
1st Target up-side 1.89
2nd Target up-side 2.06
3rd Target up-side 2.23
1st Target down-side 1.41
2nd Target down-side 1.24
3rd Target down-side 1.07
CBLI Other Details
Segment EQ
Market Capital 56058304.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cbiolabs.com
CBLI Address
73 High Street
Buffalo, NY 14203
United States
Phone: 716-849-6810
Fax: 716-849-6820
CBLI Latest News
Interactive Technical Analysis Chart Cleveland BioLabs, Inc. ( CBLI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cleveland BioLabs, Inc.
CBLI Business Profile
Cleveland BioLabs, Inc., incorporated on June 5, 2003, is a clinical-stage biotechnology company with a focus on oncology drug development. The Company’s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy. As of December 31, 2011, the Company had nine product candidates in its pipeline that are developed directly by the Company and its majority owned subsidiaries. The products include CBLB502, CBLB502, CBLB502, CBLB612, CBLC102, CBLC137, Revercom, Mobilan, Arkil, Antimycon, and Xenomycins. As of December 31, 2011, the Company had an approximately 75.8% ownership interest in Incuron, LLC (Incuron).As of December 31, 2011, the Company had an ownership stake of approximately 54.6% in Panacela Labs, Inc. (Panacela). The Company proposed to develop pharmacological agents capable of temporarily and reversibly suppressing apoptotic cell death under such stress conditions in order to reduce tissue damage and improve organism survival. The Company's is focused on two classes of these compounds, which the Company refers to as Protectans: CBLB500 and CBLB600. CBLB500 and CBLB600 series compounds are injectable biologics that act through stimulation of specific mammalian cell surface receptors that regulate innate immunity, Toll-like receptors 5 and 2 (TLR5 and TLR2).TLRs act as molecular sensors to detect the presence of pathogens and induce an appropriate innate immune response. CBLB500 series compounds are pharmacologically optimized derivatives of the Salmonella flagellin protein and CBLB600s are synthetic lipopeptides that mimic properties of mycoplasma products. The Company’s CBLB502 is lead compound in the CBLB500 series of Protectans. CBLB502 is an engineered derivative of the Salmonella flagellin protein that is designed to retain its specific TLR5-activating capacity while increasing its stability, reducing its immunogenicity and enabling high-yield production. The Company's studies have shown that CBLB502 has in vivo tissue protective effects in animal models of a number of tested scenarios, including protection against death following acute high-dose radiation exposure, protection of healthy tissues (but not tumors) from radiation and chemotherapy in cancer treatment models, and alleviation of ischemia-reperfusion-induced acute kidney injury. CBLB502 may be used as a targeted anti-cancer agent. CBLB502 may also be used as an adjuvant to standard anti-cancer radiation and chemotherapy. The Company has conducted multiple in vitro and in vivo experiments that showed CBLB502-mediated protection is limited to normal, non-cancerous cells.